American CryoStem Announces Dr. Sanjay Batra as Chairman of the Medical & Scientific Advisory Board
28 Febbraio 2013 - 3:25PM
American CryoStem Corporation (CRYO) (OTCQB:CRYO), a leading
biotech company in the field of Regenerative Medicine, is pleased
to announce today that Sanjay Batra, PhD, FACC has been appointed
as Chairman of the Medical & Scientific Advisory Board.
Dr. Batra brings 20 years of global healthcare and
entrepreneurial experience in biotech and large pharma. Dr. Batra
was Vice President, R&D Pharmaceuticals, Asia-Pacific &
Japan at Johnson & Johnson. Most recently, Dr. Batra served as
President and CEO of Aesthetic Factors, LLC, an emerging company
providing autologous, point-of-care therapies in Regenerative
Medicine. In this role, Dr. Batra led the commercial growth of
their platelet-rich plasma and autologous fat products and was
instrumental in establishing the company as the science driven
leader.
"It is a pleasure to have someone of Dr. Batra's experience lead
our Medical & Scientific Advisory Board as we advance our
'best-in-class' tissue based products and services. Dr. Batra is
highly accomplished and respected within the medical community and
will no doubt make contributions while guiding our company across
all segments of the Regenerative Medicine Industry," said John
Arnone, Chairman of American CryoStem.
Dr. Batra stated, "I am very impressed with the technology
platform and commercial applications pioneered by American
CryoStem. The company has built a world-class team focused on
the scientific advancement and commercialization of their
technologies. I look forward to being part of an organization
participating in one of the most rapidly emerging global markets in
the health industry."
About American CryoStem: American CryoStem
Corporation (OTCQB:CRYO) is a leading biotech company focused on
marketing its clinical processing services and patented products
for adipose (fat) tissue and adipose derived adult stem cells. Our
clinical tissue processing, patented cell culture media products
and tissue storage platform supports cosmetic and regenerative
medicine applications being developed globally. The Company
provides high quality, clinically processed viable cells, while at
the same time developing cutting edge applications, therapies,
patented laboratory products and services for consumer and
commercial applications.
Cautionary Statements Concerning Forward-Looking Statements
This Press Release contains "forward-looking" statements as
defined in the Private Securities Litigation Reform Act of 1995.
These statements are based on management's current expectations or
predictions of future conditions, events or results based on
various assumptions and management's estimates of trends and
economic factors in the markets in which we are active, as well as
our business plans. Words such as "expects", "anticipates",
"intends", "plans", "believes", "seeks", "estimates", "projects",
"forecasts", "may", "should", variations of such words and similar
expressions are intended to identify such forward-looking
statements. The forward-looking statements may include, without
limitation, statements regarding product development, product
potential or financial performance. The forward-looking statements
are subject to risks and uncertainties, which may cause results to
differ materially from those set forth in the statements.
Forward-looking statements in this release should be evaluated
together with the many uncertainties that affect the business of
American CryoStem Corp. and its markets, particularly those
discussed in the risk factors and cautionary statements in filings
made by the Company with the Securities and Exchange Commission.
Forward-looking statements are not guarantees of future
performance, and actual results may differ materially from those
projected. The forward-looking statements are representative only
as of the date they are made, and the Company assumes any
responsibility to update any forward-looking statements, whether as
a result of new information, future events or otherwise.
CONTACT: Investor Relations Contact:
American CryoStem Corporation
John DiFolco
732-747-1007
info@americancryostem.com
www.americancryostem.com
Grafico Azioni American Cryostem (CE) (USOTC:CRYO)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni American Cryostem (CE) (USOTC:CRYO)
Storico
Da Giu 2023 a Giu 2024